Moreau P et al. Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma. Results of the prospective IFM 2013-04 trial. Proc ASH 2015;Abstract 393.

Avet-Loiseau H et al. Impact of cytogenetics on outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide plus low-dose dexamethasone in the FIRST (MM-020) trial. Proc ASH 2015;Abstract 730.

Avet-Loiseau H et al. Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients with relapsed multiple myeloma based on cytogenetic risk status: Subgroup analysis from the phase 3 study Aspire (NCT01080391). Proc ASH 2015;Abstract 731.

Ramasamy K et al. Safety of treatment (Tx) with pomalidomide (POM) and low-dose dexamethasone (LoDEX) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) and renal impairment (RI), including those on dialysis. Proc ASH 2015;Abstract 374.

Cook G et al. A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): Results from the Myeloma X (Intensive) trial. Proc ASH 2015;Abstract 394.

Shah JJ et al. Oprozomib, pomalidomide, and dexamethasone (OPomd) in patients (pts) with relapsed and/or refractory multiple myeloma (RRMM): Initial results of a phase 1b study (NCT01999335). Proc ASH 2015;Abstract 378.

Wechalekar A et al. Oral doxycycline improves outcomes of stage III AL amyloidosis — A matched case control study. Proc ASH 2015;Abstract 732.

Dr Raje is Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.